Halozyme Appoints David Ramsay as President Drug Delivery

About this update from Halozyme Therapeutics, Inc.

SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026.In this newly created role, Mr. Ramsay will have an enterprise-wide, cross-technology mandate, and will be responsible for driving the growth of Halozyme's drug delivery technologies by establishing clear strategic priorities and assuring best in class business development and alliance management. David will report to Helen Torley, President and Chief Executive Officer."I am delighted to have a business leader of David's experience assume this new position at a time of unprecedented opportunity and growth for Halozyme. In his recent role as Interim Chief Financial Officer, he demonstrated his deep experience and an expansive skillset including strategic assessment, industry and partner knowledge, and, of course, deep financial expertise," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I look forward to having David assume this newly established leadership role and contribute to the acceleration of value creation for our shareholders."Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up.David served as Interim Chief Financial Officer of Halozyme from March 23 to June 8, 2026, until the appointment of Darren Snellgrove as Chief Financial Officer, and was responsible for leading all financial operations for the Company.He previously served as Halozyme's Chief Financial Officer from 2003 to 2009, Vice President of Corporate Development from 2009-2013 and again as Chief Financial Officer from 2013 to 2015, during which time the company evolved from a private enterprise to a billion‑dollar public biopharmaceutical company. During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018."I am thrilled to assume this new role at Halozyme at such an impor...

View stock analysis, news, and events for Halozyme Therapeutics, Inc.